Ocular Therapeutix (OCUL) Competitors $8.50 +0.05 (+0.59%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends OCUL vs. TGTX, VKTX, BBIO, CRNX, KRYS, ACLX, ADMA, RARE, BHVN, and APLSShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. TG Therapeutics Viking Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Krystal Biotech Arcellx ADMA Biologics Ultragenyx Pharmaceutical Biohaven Apellis Pharmaceuticals Ocular Therapeutix (NASDAQ:OCUL) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment. Which has stronger valuation & earnings, OCUL or TGTX? TG Therapeutics has higher revenue and earnings than Ocular Therapeutix. TG Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$61.44M21.75-$80.74M-$1.32-6.44TG Therapeutics$264.79M18.93$12.67M-$0.10-322.00 Does the media refer more to OCUL or TGTX? In the previous week, TG Therapeutics had 2 more articles in the media than Ocular Therapeutix. MarketBeat recorded 4 mentions for TG Therapeutics and 2 mentions for Ocular Therapeutix. TG Therapeutics' average media sentiment score of 1.31 beat Ocular Therapeutix's score of 0.72 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer OCUL or TGTX? Ocular Therapeutix currently has a consensus price target of $16.71, indicating a potential upside of 96.64%. TG Therapeutics has a consensus price target of $40.67, indicating a potential upside of 26.29%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, research analysts clearly believe Ocular Therapeutix is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the MarketBeat Community believe in OCUL or TGTX? TG Therapeutics received 220 more outperform votes than Ocular Therapeutix when rated by MarketBeat users. Likewise, 76.57% of users gave TG Therapeutics an outperform vote while only 70.14% of users gave Ocular Therapeutix an outperform vote. CompanyUnderperformOutperformOcular TherapeutixOutperform Votes43770.14% Underperform Votes18629.86% TG TherapeuticsOutperform Votes65776.57% Underperform Votes20123.43% Is OCUL or TGTX more profitable? TG Therapeutics has a net margin of -5.42% compared to Ocular Therapeutix's net margin of -283.74%. TG Therapeutics' return on equity of -8.32% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-283.74% -45.18% -30.87% TG Therapeutics -5.42%-8.32%-3.40% Which has more volatility and risk, OCUL or TGTX? Ocular Therapeutix has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Do insiders and institutionals have more ownership in OCUL or TGTX? 59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 3.5% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryTG Therapeutics beats Ocular Therapeutix on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-6.4410.5991.3417.19Price / Sales21.75195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book10.765.104.794.78Net Income-$80.74M$151.51M$120.07M$225.60M7 Day Performance-2.19%-2.15%-1.90%-1.23%1 Month Performance-0.23%-3.14%11.45%3.37%1 Year Performance105.81%11.50%30.63%16.58% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix3.6461 of 5 stars$8.50+0.6%$16.71+96.6%+116.8%$1.34B$61.44M-6.44267Positive NewsTGTXTG Therapeutics4.3127 of 5 stars$34.81+8.7%$40.67+16.8%+87.1%$5.42B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2931 of 5 stars$48.02+2.1%$106.75+122.3%+139.8%$5.35BN/A-51.5620Analyst ForecastGap UpBBIOBridgeBio Pharma4.6974 of 5 stars$27.67+0.7%$47.69+72.4%-30.7%$5.23B$217.77M-11.63400CRNXCrinetics Pharmaceuticals4.0778 of 5 stars$54.28+1.2%$70.82+30.5%+55.4%$5.03B$1.04M-14.39210Positive NewsKRYSKrystal Biotech4.5187 of 5 stars$172.13+5.2%$206.67+20.1%+45.9%$4.95B$50.70M92.45229Analyst ForecastACLXArcellx3.1377 of 5 stars$85.00+1.4%$105.93+24.6%+49.1%$4.60B$155.82M-118.03130Positive NewsADMAADMA Biologics3.7751 of 5 stars$19.05+2.5%$21.25+11.5%+325.4%$4.50B$382.81M68.32530RAREUltragenyx Pharmaceutical4.4444 of 5 stars$46.11+0.7%$87.46+89.7%-2.6%$4.26B$434.25M-7.081,276Analyst ForecastNews CoverageBHVNBiohaven3.7186 of 5 stars$41.38+7.6%$63.00+52.2%-4.4%$4.18B$462.51M-4.11239Analyst ForecastAPLSApellis Pharmaceuticals4.563 of 5 stars$33.37+0.5%$49.94+49.7%-39.6%$4.15B$396.59M-16.35702Analyst DowngradePositive News Related Companies and Tools Related Companies TGTX Competitors VKTX Competitors BBIO Competitors CRNX Competitors KRYS Competitors ACLX Competitors ADMA Competitors RARE Competitors BHVN Competitors APLS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCUL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
